Leukocyte composition of human breast cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 8, 2012, Pages 2796-2801

  Ruffell, Brian ^a   Au, Alfred ^a,b   Rugo, Hope S ^b,c   Esserman, Laura J ^b,c   Hwang, E Shelley ^b,c   Coussens, Lisa M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Inflammation; Macrophage

Indexed keywords

GRANZYME B;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; CD4 CD8 RATIO; CELL TYPE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; LYMPHOCYTE ACTIVATION; MYELOID DENDRITIC CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TISSUE SECTION; TUMOR MICROENVIRONMENT;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINEAGE; CELL MOVEMENT; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; LEUKOCYTES; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MYELOID CELLS; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; PHENOTYPE; T-LYMPHOCYTES; TUMOR MARKERS, BIOLOGICAL;

EID: 84857391089     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1104303108     Document Type: Article

References (62)

1. DeNardo DG, et al. (2009) CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16:91-102.
2. Ménard S, et al. (1997) Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res 3:817-819. (Pubitemid 27244351)
3. Pupa SM, et al. (1996) Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas. J Clin Oncol 14:85-94. (Pubitemid 26020000)
4. Bingle L, Brown NJ, Lewis CE (2002) The role of tumour-associated macrophages in tumour progression: Implications for new anticancer therapies. J Pathol 196:254-265. (Pubitemid 34189413)
5. Mukhtar RA, Nseyo O, Campbell MJ, Esserman LJ (2011) Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn 11:91-100.
6. DeNardoDG, et al. (2011) Leukocyte complexity in breast cancer predicts overall survival and functionally regulates response to chemotherapy. Cancer Discovery 1:54-67.
7. Esserman LJ, et al. (2006) Magnetic resonance imaging captures the biology of ductal carcinoma in situ. J Clin Oncol 24:4603-4610. (Pubitemid 46630958)
8. Volodko N, Reiner A, Rudas M, Jakesz R (1998) Tumour-associated macrophages in breast cancer and their prognostic correlations. Breast 7:99-105. (Pubitemid 28230834)
9. Lee AH, Happerfield LC, Bobrow LG, Millis RR (1997) Angiogenesis and inflammation in invasive carcinoma of the breast. J Clin Pathol 50:669-673. (Pubitemid 27396070)
10. Uzzan B, Nicolas P, Cucherat M, Perret GY (2004) Microvessel density as a prognostic factor in women with breast cancer: A systematic review of the literature and meta-analysis. Cancer Res 64:2941-2955. (Pubitemid 38581387)
11. Tsutsui S, et al. (2005) Macrophage infiltration and its prognostic implications in breast cancer: The relationship with VEGF expression and microvessel density. Oncol Rep 14:425-431.
12. Bolat F, et al. (2006) Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: Correlations with prognostic parameters. J Exp Clin Cancer Res 25:365-372. (Pubitemid 44763728)
13. Chen JJ, et al. (2005) Tumor-associated macrophages: The double-edged sword in cancer progression. J Clin Oncol 23:953-964. (Pubitemid 46202315)
14. Leek RD, et al. (1996) Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56:4625-4629. (Pubitemid 26338061)
15. Campbell MJ, et al. (2010) Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat 128:703-711.
16. Robinson BD, et al. (2009) Tumor microenvironment of metastasis in human breast carcinoma: A potential prognostic marker linked to hematogenous dissemination. Clin Cancer Res 15:2433-2441.
17. Guy CT, Cardiff RD, Muller WJ (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol Cell Biol 12:954-961.
18. Lin EY, Nguyen AV, Russell RG, Pollard JW (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193:727-740.
19. Lin EY, et al. (2006) Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 66:11238-11246. (Pubitemid 46009952)
20. Stockmann C, et al. (2008) Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456:814-818.
21. Lin EY, et al. (2007) Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Mol Oncol 1:288-302. (Pubitemid 350181649)
22. Wyckoff J, et al. (2004) A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 64:7022-7029. (Pubitemid 39331012)
23. Wyckoff JB, et al. (2007) Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 67:2649-2656. (Pubitemid 46548952)
24. Doedens AL, et al. (2010) Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res 70:7465-7475.
25. Aspord C, et al. (2007) Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med 204:1037-1047. (Pubitemid 46798148)
26. Pedroza-Gonzalez A, et al. (2011) Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med 208:479-490.
27. Gocheva V, et al. (2010) IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev 24:241-255.
28. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8:59-73.
29. Allan CP, Turtle CJ, Mainwaring PN, Pyke C, Hart DN (2004) The immune response to breast cancer, and the case for DC immunotherapy. Cytotherapy 6:154-163. (Pubitemid 38714811)
30. Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141:39-51.
31. Pulford KA, Sipos A, Cordell JL, Stross WP, Mason DY (1990) Distribution of the CD68 macrophage/myeloid associated antigen. Int Immunol 2:973-980. (Pubitemid 20330547)
32. Kunz-Schughart LA, et al. (2003) [The "classical" macrophage marker CD68 is strongly expressed in primary human fibroblasts]. Verh Dtsch Ges Pathol 87:215-223.
33. Hintzen RQ, et al. (1994) Characterization of the human CD27 ligand, a novel member of the TNF gene family. J Immunol 152:1762-1773. (Pubitemid 24075708)
34. Hamann D, et al. (1997) Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med 186:1407-1418. (Pubitemid 27479800)
35. Okada R, Kondo T, Matsuki F, Takata H, Takiguchi M (2008) Phenotypic classification of human CD4+ T cell subsets and their differentiation. Int Immunol 20:1189-1199.
36. Nelson BH (2010) CD20+ B cells: The other tumor-infiltrating lymphocytes. J Immunol 185:4977-4982.
37. Liu W, et al. (2006) CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 203:1701-1711. (Pubitemid 44036276)
38. Kunkel EJ, et al. (2002) Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes. Am J Pathol 160:347-355.
39. Kim CH, et al. (2001) Rules of chemokine receptor association with T cell polarization in vivo. J Clin Invest 108:1331-1339. (Pubitemid 33107761)
40. Beatty GL, et al. (2011) CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331:1612-1616.
41. Demaria S, et al. (2001) Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 7:3025-3030. (Pubitemid 32963819)
42. Denkert C, et al. (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:105-113.
43. Bates GJ, et al. (2006) Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24:5373-5380. (Pubitemid 46623168)
44. Ladoire S, et al. (2008) Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res 14:2413-2420. (Pubitemid 351551075)
45. de Kruijf EM, et al. (2010) The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res 16:1272-1280.
46. Macchetti AH, et al. (2006) Tumor-infiltrating CD4+ T lymphocytes in early breast cancer reflect lymph node involvement. Clinics (Sao Paulo) 61:203-208. (Pubitemid 44047807)
47. Sheu BC, et al. (2008) Clinical significance of tumor-infiltrating lymphocytes in neoplastic progression and lymph node metastasis of human breast cancer. Breast 17:604-610.
48. Mahmoud SM, et al. (2011) Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29:1949-1955.
49. Gottfried E, et al. (2008) Expression of CD68 in non-myeloid cell types. Scand J Immunol 67:453-463. (Pubitemid 351519391)
50. Pilling D, Fan T, Huang D, Kaul B, Gomer RH (2009) Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS ONE 4:e7475.
51. Shao DD, Suresh R, Vakil V, Gomer RH, Pilling D (2008) Pivotal Advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J Leukoc Biol 83:1323-1333. (Pubitemid 351960310)
52. Azambuja D, et al. (May 2, 2011) Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol, 10.1093/annonc/mdr157.
53. Sharma M, et al. (2010) Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ. Breast Cancer Res Treat 123:397-404.
54. Beck AH, et al. (2009) The macrophage colony-stimulating factor 1 response signature in breast carcinoma. Clin Cancer Res 15:778-787.
55. Trimboli AJ, et al. (2009) Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 461:1084-1091.
56. Erez N, Truitt M, Olson P, Arron ST, Hanahan D (2010) Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 17:135-147.
57. Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6:392-401.
58. Schmielau J, Finn OJ (2001) Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 61:4756-4760. (Pubitemid 32691887)
59. Fridlender ZG, et al. (2009) Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 16:183-194.
60. Eller K, et al. (2011) IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune suppression. J Immunol 186:83-91.
61. Galli SJ, Nakae S, Tsai M (2005) Mast cells in the development of adaptive immune responses. Nat Immunol 6:135-142. (Pubitemid 40268194)
62. Perrigoue JG, et al. (2009) MHC class II-dependent basophil-CD4+ T cell interactions promote T(H)2 cytokine-dependent immunity. Nat Immunol 10:697-705.